Working… Menu

Study of CAD-1883 for Spinocerebellar Ataxia (Synchrony-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04301284
Recruitment Status : Withdrawn (In January 2021 Novartis acquired Cadent Therapeutics. As part of a pipeline reassessment, the Synchrony-1 trial will not proceed as initially scheduled.)
First Posted : March 10, 2020
Last Update Posted : April 8, 2021
Information provided by (Responsible Party):
Cadent Therapeutics

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : December 2022